Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1983 1
1984 1
1985 1
1989 1
1990 1
1992 6
1993 1
1994 1
1995 1
1996 2
1997 2
1999 7
2000 4
2001 4
2002 5
2003 4
2004 6
2005 3
2006 3
2007 3
2008 2
2009 4
2010 5
2011 3
2012 4
2014 5
2015 5
2016 5
2017 4
2018 5
2019 8
2020 6
2021 6
2022 9
2023 11

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Rare Breast Cancer Subtypes.
Jenkins S, Kachur ME, Rechache K, Wells JM, Lipkowitz S. Jenkins S, et al. Among authors: lipkowitz s. Curr Oncol Rep. 2021 Mar 23;23(5):54. doi: 10.1007/s11912-021-01048-4. Curr Oncol Rep. 2021. PMID: 33755810 Free PMC article. Review.
Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.
Tang J, Tu S, Lin G, Guo H, Yan C, Liu Q, Huang L, Tang N, Xiao Y, Pope RM, Rajaram MVS, Amer AO, Ahmer BM, Gunn JS, Wozniak DJ, Tao L, Coppola V, Zhang L, Langdon WY, Torrelles JB, Lipkowitz S, Zhang J. Tang J, et al. Among authors: lipkowitz s. J Exp Med. 2020 Apr 6;217(4):e20182091. doi: 10.1084/jem.20182091. J Exp Med. 2020. PMID: 31999304 Free PMC article.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Lampert EJ, et al. Among authors: lipkowitz s. Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12. Clin Cancer Res. 2020. PMID: 32398324 Free PMC article. Clinical Trial.
ONC201: Stressing tumors to death.
Endo Greer Y, Lipkowitz S. Endo Greer Y, et al. Among authors: lipkowitz s. Sci Signal. 2016 Feb 16;9(415):fs1. doi: 10.1126/scisignal.aad7955. Sci Signal. 2016. PMID: 26884598 Free PMC article. Review.
Pümpfrage redivivus.
Stone B, Lipkowitz S. Stone B, et al. Among authors: lipkowitz s. JAMA. 2009 Aug 12;302(6):626; author reply 626. doi: 10.1001/jama.2009.1103. JAMA. 2009. PMID: 19671903 Free PMC article. No abstract available.
Mathematical models of breast and ovarian cancers.
Botesteanu DA, Lipkowitz S, Lee JM, Levy D. Botesteanu DA, et al. Among authors: lipkowitz s. Wiley Interdiscip Rev Syst Biol Med. 2016 Jul;8(4):337-62. doi: 10.1002/wsbm.1343. Epub 2016 Jun 3. Wiley Interdiscip Rev Syst Biol Med. 2016. PMID: 27259061 Free PMC article. Review.
Update on PARP Inhibitors in Breast Cancer.
Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Zimmer AS, et al. Among authors: lipkowitz s. Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Curr Treat Options Oncol. 2018. PMID: 29644491 Free PMC article. Review.
128 results